CDH2 and glioma: Immunofluorescence detection revealed that in glioma cells overexpressing miR‐192, the mesenchymal transition marker (N‐cad) was significantly downregulated (1.316 ± 0.341 vs. 18.35 ± 1.217; *p < 0.05).